Benralizumab for Asthma

(ROSY-F Trial)

This trial aims to provide ongoing access to benralizumab for individuals who completed a previous related study and are considered to benefit from its continued use. The focus is on monitoring the long-term safety and effectiveness of benralizumab, an injectable medication for asthma. Participants should have taken part in an earlier study with benralizumab and believe it helps manage their asthma symptoms. As a Phase 3 trial, this study represents the final step before FDA approval, offering participants a chance to contribute to the validation of a promising asthma treatment.

The trial does not specify if you need to stop taking your current medications, but you cannot use live vaccines or certain biologic therapies unless no alternatives are available for your condition.

Previous studies have shown that benralizumab is safe for treating severe eosinophilic asthma. Research found that most patients experienced only mild side effects, such as headaches and joint pain. In another study, patients reported only two mild side effects. Over the long term, benralizumab was well tolerated, with mild side effects in just over 21% of patients. While some patients experienced minor issues, the treatment remained generally manageable. Overall, evidence suggests that benralizumab is safe and well tolerated for those considering joining a clinical trial.¹²³⁴⁵

Unlike the standard asthma treatments, which often include inhaled corticosteroids or long-acting beta-agonists, Benralizumab is unique because it specifically targets and depletes eosinophils, a type of white blood cell that can contribute to inflammation in asthma. This biologic drug is administered via subcutaneous injection, offering a different approach from traditional inhaled treatments. Researchers are excited about Benralizumab because it has the potential to provide better control of asthma symptoms by addressing a root cause of inflammation, potentially leading to fewer asthma attacks and improved lung function for patients with severe eosinophilic asthma.

Research has shown that benralizumab, which participants in this trial will receive, can significantly help people with asthma. Studies have found that benralizumab reduces asthma flare-ups and improves breathing. Many patients experienced fewer asthma attacks and required less steroid medication. Benralizumab works by targeting and reducing certain immune cells called eosinophils, which can cause asthma symptoms. These findings suggest that benralizumab can effectively manage asthma.